Jakavi (Ruxolitinib Phosphate)

Name: Jakavi
Brand: Novartis
SKU: 6917
Availability: InStock

Type

Product

Manufacturer

Country

Dosage

Qty-Price (USD)

Type:

Product: Jakavi

Manufacturer: Novartis

Country: Canada

Dosage: 5 mg

Qty-Price (USD):

Type:

Product: Jakavi

Manufacturer: Novartis

Country: Turkey

Dosage: 5 mg

Qty-Price (USD):

Type:

Product: Jakavi

Manufacturer: Novartis

Country: Canada

Dosage: 10 mg

Qty-Price (USD):

Type:

Product: Jakavi

Manufacturer: Novartis

Country: Canada

Dosage: 15 mg

Qty-Price (USD):

Type:

Product: Jakavi (ON BACKORDER)

Manufacturer: Novartis

Country: Turkey

Dosage: 15 mg

Qty-Price (USD):

Type:

Product: Jakavi

Manufacturer: Novartis

Country: Canada

Dosage: 20 mg

Qty-Price (USD):

Generic Equivalent of Jakavi

Type

Product

Manufacturer

Country

Dosage

Qty-Price (USD)

There is no generic product of Jakavi.

Jakavi Information

Jakavi at CanadaPharmacyOnline.com

The manufacturer of the brand-name Jakavi is Novartis. It is available in many countries worldwide, including Canada and Turkey.

The generic ruxolitinib phosphate is currently unavailable (at this pharmacy).

Dosage:

Jakavi is available in the following oral strengths at this pharmacy:
• Tablets: 5 mg, 10 mg, 15 mg, and 20 mg.

Dosage is individualized and based on your condition. For myelofibrosis, the starting dose is 5-20 mg twice daily, based on platelet count. The starting dose for polycythemia vera is 10 mg twice daily, while for GvHD, it is 5 mg to 10 mg twice daily. Do not stop Jakavi suddenly without medical supervision; doses should be tapered gradually to avoid a rebound worsening of symptoms.

Usage:

Jakavi (ruxolitinib) is a Janus kinase (JAK1 and JAK2) inhibitor approved for the treatment of myelofibrosis (an abnormal bone marrow disorder affecting blood cell production), polycythemia vera (a disorder causing too many red blood cells), and steroid-refractory acute or chronic graft-versus-host disease (GvHD) following stem cell transplantation. Blood counts are monitored closely during treatment, particularly in the first months, due to the risk of low blood cell counts.

Mechanism of Action
Ruxolitinib selectively inhibits Janus kinases 1 and 2 (JAK1 and JAK2). The JAK-STAT pathway is a cellular signaling cascade that controls the production and function of blood cells. In myelofibrosis and polycythemia vera, mutations (particularly in the JAK2 gene) permanently overactivate this pathway, leading to uncontrolled blood cell production and bone marrow scarring. By blocking JAK1 and JAK2, ruxolitinib reduces this dysregulated signaling, decreasing symptoms such as an enlarged spleen, fatigue, and abnormal blood counts. In GvHD, ruxolitinib suppresses the excessive immune response by donor T-cells against the recipient's tissues.

Take Jakavi exactly as your hematologist or oncologist prescribes, as directed in the Product Monograph. Blood tests will be required frequently, especially when starting treatment. Jakavi may be taken with or without food. It may also be administered via a nasogastric (NG) tube if needed.

The information below summarizes some, but not all, potential side effects, risks, and interactions. Before starting Jakavi, it is essential to discuss all possible side effects, risks, and interactions with your doctor or pharmacist.

Side Effects:

The information below outlines potential side effects of Jakavi (ruxolitinib). It is not an exhaustive list, and individual reactions can vary.

Common side effects: These are common side effects of Jakavi; other side effects are possible. Contact your doctor promptly if any side effects are persistent, worsening, or concerning.
• Anemia (low red blood cells) — one of the most frequent effects; you may require blood transfusions.
• Bruising or unusual bleeding
• Dizziness or headache
• Increased infections due to immune suppression
• Low platelet count (thrombocytopenia)
• Weight gain

Serious Side Effects: Seek immediate medical attention or call emergency services if you experience any of the following symptoms:
• Progressive Multifocal Leukoencephalopathy (PML): Confusion, weakness, vision changes, or difficulty speaking or walking. This rare but serious brain infection caused by the JC virus has been reported.
• Rebound Symptoms on Withdrawal: Rapid return of myelofibrosis symptoms (spleen enlargement, fever, pain) if Jakavi is stopped suddenly. Always taper the dose gradually under medical supervision.
• Secondary Malignancies: Lymphoma and other malignancies have been reported with JAK inhibitors. Report any new lumps, lymph node swelling, or unusual symptoms promptly.
• Serious Infections: Fever, chills, cough, or other signs of infection. Jakavi suppresses the immune system and increases the risk of bacterial, fungal, and viral infections, including tuberculosis, fungal pneumonia, and herpes zoster (shingles) reactivation of herpes zoster (shingles). Screening for tuberculosis is required before starting treatment.
• Severe Allergic Reaction: Hives, swelling of the face, lips, tongue, or throat, or difficulty breathing.

Contraindications:

Do not take Jakavi/ruxolitinib if:
• Allergies: Known hypersensitivity to ruxolitinib or any ingredient in the tablet.

Tell your doctor about all of your medical conditions, past and present, before starting Jakavi. This is crucial as certain conditions affect the drug's safety.
• A history of cancer
• All vaccinations (live vaccines must be avoided during treatment)
• Any current infections
• Kidney or liver disease
• Tuberculosis exposure

Drug Interactions:

Before taking Jakavi, discuss all potential risks and interactions with your doctor or pharmacist. For complete information, please refer to the product monograph at https://pdf.hres.ca/dpd_pm/00043802.PDF.

Provide your doctor with a complete list of all your medications, including prescriptions, over-the-counter (OTC) drugs, vitamins, herbal supplements, recreational drugs, and any significant dietary changes, as these may interact with Jakavi. Jakavi may interact with other medicines, including but not limited to:
• CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin): Reduce ruxolitinib levels and effectiveness.
• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, grapefruit juice): Significantly increase ruxolitinib levels; dose reduction of Jakavi is required. Avoid grapefruit juice.
• Other immunosuppressants: Additive immune suppression; increased infection risk.

Pregnancy and Breastfeeding:

Inform your doctor if you are pregnant or planning to become pregnant. Jakavi may cause harm to an unborn baby. Women of childbearing potential should use effective contraception during treatment. Do not use Jakavi during pregnancy unless the benefits clearly outweigh the risks; discuss with your doctor. Consult your doctor to weigh the benefits and risks of this medicine before using it while nursing. Breastfeeding must be discontinued while taking Jakavi and for at least 2 weeks after the final dose.

Use in Children:

Jakavi is approved for use in children aged 12 years and older for the treatment of acute and chronic graft-versus-host disease (cGvHD). For other indications, the safety and efficacy in children under 18 years of age have not been fully established. Dosing in eligible children is guided by a specialist.

Frequently Asked Questions about Jakavi at Canada Pharmacy Online

Why is Jakavi more affordable in Canada than in the United States?

Prescription drug prices, including Jakavi, are generally lower in Canada than in the U.S. due to a combination of factors, primarily government price regulations, differing market dynamics, and other economic considerations. In Canada, provincial and federal governments negotiate drug prices with pharmaceutical companies, which often results in lower prices than in the U.S., where market forces play a more significant role. For more information, see the FAQs on Prescription Drug Importation from the Kaiser Family Foundation (KFF): https://www.kff.org/health-costs/issue-brief/faqs-on-prescription-drug-importation/

How much is the shipping?

Our shipping fee is a flat rate of $10.00 per order. Our pharmacy is dedicated to offering you the lowest prices on high-quality products.

How do I place an order with your pharmacy?

Ordering from us is very simple. You can purchase online or call Customer Service at 1.866.920.3784; for more information or to learn about the ordering process, visit our How to Order page.

Is there a limit on how many Jakavi I can order at once?

CanadaPharmacyOnline.com can dispense up to a 3-month supply of Jakavi per your doctor's prescription.

Can I buy Jakavi from you over the counter?

No, Jakavi requires a valid prescription from your doctor. We do not sell this product without a valid prescription.

Do you ship to the United States?

Yes, we do. It usually takes between 7 and 18 business days to receive your order from our pharmacy.

Is there a generic for Jakavi?

No, the generic alternative is currently unavailable (at this pharmacy).

Blog Post:

The Financial Burden of Cancer Medications; What the US Needs to Learn from Canada

Latest News:

Partners in Care Managing Erectile Dysfunction in Prostate Cancer (news published on June 20, 2026)

Similar Drugs in the category of Cancer Medications:

Arimidex Nolvadex Zofran Gleevec Femara

The information on this page is sourced from independent third parties contracted by CanadaPharmacyOnline. While we cannot guarantee its medical accuracy, we strongly recommend consulting a healthcare professional for personalized advice regarding medications or medical conditions.

Reviews From Real Customers